---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-000621"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:05:31.765526+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics prelim Q4 rev ~$4.8M (+31% YoY); FY rev ~$18.2M (+41% YoY); cash $8.6M

## Summary
- Q4 2023 revenue estimated $4.7-4.9M, up from $3.6M in Q4 2022 (30-36% YoY increase).
- FY 2023 revenue estimated $18.1-18.3M, up from $12.9M in FY 2022 (40-42% YoY increase).
- Cash at Dec 31, 2023 estimated $8.6M vs $20.5M a year ago; Q4 cash burn improved to $1.7M from $3.6M.
- CEO cited strong demand for EksoNR and Indego; final results expected in March 2024.

## SEC filing metadata
- accession: 0001437749-24-000621
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000143774924000621/0001437749-24-000621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000143774924000621/ekso20240104_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-000621
- JSON: https://secwatch.observer/filing/0001437749-24-000621.json
- Plain text: https://secwatch.observer/filing/0001437749-24-000621.txt

## Key facts
- Earnings Releases
  EKSO BIONICS HOLDINGS, INC. reported the fiscal year ended December 31, 2023 results: revenue in the range of $18.1 million to $18.3 million.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: in the range of $18.1 million to $18.3 million
  - Result: preliminary results
  source text: Total revenue for fiscal year 2023 is estimated to be in the range of $18.1 million to $18.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000143774924000621/0001437749-24-000621-index.htm
- Earnings Releases
  EKSO BIONICS HOLDINGS, INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue in the range of $4.7 million to $4.9 million.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Revenue: in the range of $4.7 million to $4.9 million
  - Result: preliminary results
  source text: Total revenue for the fourth quarter of 2023 is estimated to be in the range of $4.7 million to $4.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000143774924000621/0001437749-24-000621-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.